Note 14 - Segments (Tables)

3 Months Ended

Mar. 31, 2020

T hree Months Ended March 31, 2020	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	15,221		$	—		$	—		$	15,221
Grant and other revenue		58,916			82,135			—			141,051
Total revenue		74,137			82,135			—			156,272
Cost of revenue		609			—			—			609
Research and development expenses		957,626			41,643			—			999,269
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			(1,522	)		1,812,433			1,810,911
Depreciation and amortization (2)		—			—			16,843			16,843
(Loss) income from operations (3)		(884,098	)		42,014			(1,829,276	)		(2,671,360	)
Other expense (4)		—			—			(2,248	)		(2,248	)
Net loss		(884,098	)		42,014			(1,831,524	)		(2,673,608	)
Total assets, net of depreciation and amortization:
United States	$	36,671		$	2,494		$	4,438,066		$	4,477,231
International		—			—			—			—
Capital expenditures		—			—			6,459			6,459

T hree Months Ended March 31, 2019	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	3,150		$	—		$	—		$	3,150
Grant and other revenue		35,991			2,483			—			38,474
Total revenue		39,141			2,483			—			41,624
Cost of revenue		6,126			—			—			6,126
Research and development expenses		740,583			—			—			740,583
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			11,714			1,680,023			1,691,737
Depreciation and amortization (2)		—			—			36,779			36,779
Loss from operations (3)		(707,568	)		(9,231	)		(1,716,802	)		(2,433,601	)
Other income (4)		—			—			8,713			8,713
Provision for income taxes		(256	)		(3	)		(617	)		(876	)
Net loss from continuing operations		(707,824	)		(9,234	)		(1,708,706	)		(2,425,764	)
Loss from discontinued operations, net of tax		(3,297	)		—			—			(3,297	)
Net loss		(711,121	)		(9,234	)		(1,708,706	)		(2,429,061	)
Total assets, net of depreciation and amortization:
United States	$	55,213		$	2,411		$	4,891,112		$	4,948,736
International		10,422			—			602			11,024
Capital expenditures		—			—			—			—